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ABSTRACT 
Flow velocity measurement in haemodialysis  
access using 4D MRI 
 
J Downs (UCT), S Jermy (UCT), B Spottiswoode (Siemens), JM du Toit (UCT), D 
Kahn (UCT), EM Meintjes (UCT), T Franz (UCT)  
 
Treatment of renal failure while awaiting transplant requires vascular access, which 
comes with both complications and failure rates. In order to improve this, 
information about the AVF or AVG itself, as well as the haemodynamics is required. 
This data will then be used for computer modelling techniques and computational 
flow dynamics. Previously, the required imaging was provided by contrasted MRI, 
contraindicated in renal failure. Haemodynamic data was prvided by, amongst other 
things, duplex Doppler. New MRI software that provides imaging data as well as 
haemodynamic information without using contrast could be used to provide new 
high-quality data for modelling.  
 
Methods: This was a prospective pilot study. Six control cases (with no history of 
vascular illness or surgery of any kind to the right upper arm), as well as three grafts 
and five fistulae underwent phase contrast MR angiography of the right upper arm 
with a Siemens Magnetom Symphony 1.5T MRI Scanner. Images were then 
processed using Supertool in Matlab, and flow velocities at predetermined points on 
the brachial artery and cephalic vein, graft and fistula were calculated.  
 
Results: Velocities ranged from 5.8 cm/sec in a volunteer’s brachial artery to 85.5 
cm/sec in an arteriovenous fistula patient’s brachial artery. Flow volumes in the 
cephalic vein or access varied from 6.9 ml/min. in a volunteer and up to 4398.1 
ml/min. in an arteriovenous fistula. Graphical representations show marked 
haemodynamic changes throughout the imaged vessels.  
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Conclusion: This technique provides good imaging and quantitative data about 
small vessel haemodynamics. 
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CHAPTER 1  
PROPOSAL 
  
1.1 Introduction  
The incidence of renal failure in sub-Saharan Africa is increasing. The treatment of 
end-stage renal disease (ESRD), while including managing causative diseases and 
complications of the ESRD, requires renal replacement therapy (RRT). Quite clearly, 
the ideal way to do this is via renal transplant. The other way to provide this is via 
dialysis to perform some functions of the failed kidney. This can be provided by two 
methods: machines performing the filtration function of the kidney on blood 
circulated through them (haemodialysis), or peritoneal dialysis, where the patient’s 
peritoneal membrane acts as a filter to remove dialysates from the blood.   
 
Although efforts are being made to minimise time on haemodialysis programmes 
and improve access to transplants, the current reality is that the average patient can 
spend (depending on various factors) months to several years on haemodialysis. In 
order for haemodialysis to take place, vascular access is required. This access must 
be safe, cause minimal complications, and not require repeated procedures for the 
patient. Currently, this is provided by the arteriovenous fistula (AVF) or 
arteriovenous graft (AVG) for haemodialysis access. These are generally peripheral 
procedures, placed most often in the upper limb, and allow a sufficiently high blood 
flow rate in a smaller peripheral vessel, which allow adequate haemodialysis to take 
place. They are, however, not without complications of their own. The most 
important of these is failure of the access itself. As each patient has only limited sites 
suitable for AVF or AVG creation (because of patient anatomy and complications 
from previous lines and procedures), every attempt should be made to make each 
access AVF or AVG the last one for that patient.  
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In order to optimise the performance of the access, information about the AVF or 
AVG itself, as well as the haemodynamics of the flow through the access, is 
required. Once this information is gathered, it could then be applied to see if 
alterations in technique or materials would improve patency rates, decrease 
maturation times, and decrease complications. 
1.2 Background  
Haemodialysis is the movement of water and solutes across a semipermeable 
membrane, using diffusion and convection, out of the patient’s circulatory system.  
Diffusion is the movement of solutes across a semipermeable membrane along a 
concentration gradient. Clearance of a solute via diffusion is dependent on many 
things – molecular weight, electrical charge, fluid concentration gradient, type of 
membrane, and blood and fluid flow rates. Convection refers to the movement of 
solvent and dissolved solutes across a semipermeable membrane along a hydrostatic 
pressure gradient. Ultrafiltration is the convective movement of water across the 
semipermeable membrane. 
 
Haemodialysis combines these principles to clear the patient’s blood of toxic waste 
products. The blood travels via an extracorporeal circuit – from patient via access, 
into the “arterial side” of the circuit. It flows through a pressure monitor, and heparin 
is added. It then enters the dialysis machine. This machine consists of a 
semipermeable membrane with two different fluid circuits flowing in opposite 
directions on either side: blood and dialysis fluid (machine characteristics differ in 
terms of membrane type, surface area, permeability characteristics and other 
components). The blood then leaves the dialysis machine and enters the “venous 
side” of the circuit. This flows through a pressure monitor and clamp mechanism (in 
case of sudden failure of the machine to stop blood from flowing out) and back into 
the so-called venous needle in the vascular access. The volume of fluid filtered off is 
regulated by the machine dictating flow rates of the dialysis fluid1. Different types of 
haemodialysis make use of varying levels of diffusion, convection and ultrafiltration, 
depending on the setting of the patient who requires dialysis. However, they all 
require a minimum flow rate of blood into the machine of 300–500 ml per minute. 
Flow velocity measurement in haemodialysis access using 4D MRI Downs J 
 
3 
In the short term, this can be provided by indwelling catheters in the central venous 
system. However, in the case of long-term dialysis, provision must be made to get 
permanent access to this high blood flow rate, all the while minimising trauma and 
complications. 
1.3 Literature review 
In the western world, chronic kidney disease (CKD) and end-stage renal disease 
(ESRD) are increasingly prevalent. CKD is the ninth leading cause of death in the 
USA1. In 2005, 106 000 patients began treatment for ESRD, and ESRD consumed 
6% of the Medicaid budget for that year. Many of the costs were associated with the 
transition onto ESRD therapy, such as catheters, vascular access procedures, failed 
access and the complications of the above treatments1.  
 
Eighty percent of the world’s population on renal replacement therapy (RRT) is in 
North America, Europe and Japan, comprising only 15% of the world’s population2. 
In sub-Saharan Africa, data is obviously more difficult to come by, but the mortality 
rate from ESRD is obviously much higher2. With the expected explosion of 
hypertension and diabetes in sub-Saharan Africa (130% by 2020), and the increasing 
burden of HIV-associated nephropathy, and therefore downstream increases in CKD 
and ESRD2, all efforts to improve and streamline management of this condition 
should be made.  
 
Management of ESRD requires provision of RRT while the patient is awaiting renal 
transplant. This can be provided in two forms: continuous ambulatory peritoneal 
dialysis, and haemodialysis. Haemodialysis requires the passage of the patient’s 
entire blood flow through the dialysis machine every 15 minutes, at flow rates of 
approximately 200–400 ml/min.3. This is far higher than the flow rate through the 
average peripheral vein. Therefore, haemodialysis either requires vascular access via 
a large bore catheter into a central vein, or an abnormal connection created between 
a peripheral artery and vein to increase blood flow through that vessel. Central 
venous access has a high rate of complications, with increased risk of infection, 
thrombosis and stenosis of the vein amongst them. Initiatives like the National 
Flow velocity measurement in haemodialysis access using 4D MRI Downs J 
 
4 
Kidney Foundation–Dialysis Outcomes Quality Initiative (NKF-DOQI), and later the 
Fistula First Breakthrough Initiative (FFBI) in North America have been working to 
increase the number of arteriovenous fistulae created and used, both in the USA and 
worldwide, in an effort to limit these complications and increase longevity of 
vascular access in RRT. 
 
Permanent vascular access can be created via two methods: by using either the 
patient’s existing vasculature (autologous), or by placing a vascular graft. In order 
for it to provide the required flows for adequate haemodialysis, an abnormal 
connection between the arterial and venous system must be created – a shunt. This 
then creates a connection between a high and a low-pressure system, allowing more 
blood to flow via the low-pressure system (the vein or graft), rather than down the 
artery. This provides sufficient flow for dialysis to take place without accessing the 
central vasculature.  
 
These shunts can theoretically be placed between any artery and vein in the body. 
However, as the goal is to provide access for as long as possible with the lowest 
complication rates, there are certain rules that are followed when an access site is 
chosen. The access is always placed as distally as possible (i.e. placed in the forearm 
rather than the upper arm) to preserve proximal sites for future use4. The upper limb 
is chosen rather than the lower limb (lower infection rates, more accessible for use, 
high incidence of lower extremity venous occlusive disease, higher incidence of 
arterial steal4). As autologous fistulae have better patency rates, they are chosen 
before grafts1.  
 
Currently, the gold standard of imaging of existing fistulae is contrast fistulography5, 
an invasive testing modality. AVFs found to be dysfunctional are then considered for 
interventions to be performed at the same time. This modality has significant 
associated complications, including contrast allergies and puncture site 
complications, such as false aneurysms. The most commonly used non-invasive 
modality is the colour-flow or duplex Doppler, which has shown reasonable 
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accuracy when compared to invasive angiography, and gives structural as well as 
flow rate information5. Flow rates can also be measured by ultrasound measurement 
of saline dilution via ultrasound probe, a well-documented non-invasive 
measurement technique6.  
 
Magnetic resonance angiography (MRA) has also been previously assessed as a 
useful imaging modality in these fistulae or grafts. It used phase contrast methods 
that measured flow in two directions of each slice. It has good sensitivity and 
specificity in comparison to contrast fistulography and doesn’t require contrast 
injection. However, the complexity of flow in these vessels was felt to be a limitation 
in the accuracy of assessing the fistulae and their complications7.   
 
However, newer technology has now permitted advances in this imaging technology. 
The complexity of flow can now be resolved using phase contrast velocity encoding 
in three dimensions, and spatial encoding in three dimensions. This allows us to 
track complex blood flow patterns though multiple segments, and track the velocity 
changes as induced by outside vectors. This data is time-resolved and ECG-gated. It 
allows for both particle tracking to follow flow patterns, as well as other 
haemodynamic data  to be calculated, such as wall stress and shear stress. It also 
provides information for computational flow dynamics to build models of vessels.  
 
1.4 Aims and objectives 
 Recruitment of study participants. 
 Performing MRI scans on each study participant. 
 Analysis of MRI data to quantify blood flow. 
 Comparison of blood flow between different patient groups and healthy 
volunteers. 
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1.5 Methods 
Patients will be recruited from the chronic haemodialysis programme at Groote 
Schuur Hospital renal unit. Healthy volunteers will also be recruited. Should they be 
willing to participate, they would then receive the patient information sheet and sign 
an informed consent letter. Their scan will then be scheduled and performed in the 
next available after-hours slot at the Groote Schuur MRI scanner. 
 
The data from the scan will then be analysed by project team members using 
MathWorks’ MATLAB image processing toolbox. This data will then be converted 
into numerical values, giving flow velocities at segmental points along the vessel 
scanned. 
 
Ethical considerations 
All study participants will receive a patient information sheet, and sign an informed 
consent before taking part in the study (see appendices). As such, they will be aware 
of the aims and objectives of the study, as well as the procedures that will occur 
during the study. Patients will be fully informed of the procedure for the scan. 
Participating in this study will not affect their treatment or position in the dialysis 
programme in any way, either positively or negatively.  
 
Inconvenience to study participants will be limited by provision of transport for 
participants to and from the scan, as well as some refreshments. They will receive no 
medications, contrast or invasive procedures. They will receive no monetary 
reimbursement. All data collected will be stored anonymously in secure servers, and 
will only be made available to study investigators. Any complaints or issues unable 
to be addressed by myself or my supervisors will be referred to the Human Research 
Ethics Committee, and contact details are available in the patient information sheets.   
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1.6 Work plan and budget 
Timeline 
Patient recruitment and MRI scanning – November 2013 to February 2014 
Data analysis by MRI experts – March 2014 to June 2014 
Dissertation preparation – June 2014 to November 2014 
Submission – November 2014 
 
Budget 
This study is funded by an NRF grant and an associated NRF staff development 
grant. This allows for payment of cost of scans, transport and study participant 
refreshments. It also funds presentation of research findings at local conferences.   
 
Provisional costing: 
 R2 000: patient transport and refreshments. 
 R3 000: cost per MRI of study subject. 
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CHAPTER 2  
LITERATURE REVIEW 
  
2.1 Introduction 
The prevalence of chronic kidney disease (CKD) and end-stage renal disease 
(ESRD) has increased significantly in recent years. CKD is the ninth leading cause 
of death in the USA1. In 2013, 117 162 new cases of ESRD were reported. Renal 
replacement therapy (RRT) is expensive. Many of the costs of treatment are 
associated with the transition onto ESRD therapy, such as catheters, vascular access 
procedures, failed access and the complications of the above procedures2. Eighty 
percent of the world’s population on RRT is in North America, Europe and Japan, 
which comprise only 15% of the world’s total population3. In South Africa in 2012, 
164 patients per million population were on renal replacement therapy4. The 
mortality rate from ESRD in developing countries is much higher than in the 
developed world3. With the expected increase of hypertension and diabetes in sub- 
Saharan Africa (130% increase by 2020) and the ever-increasing burden of HIV-
associated nephropathy, and therefore downstream increases in CKD and ESRD, all 
efforts to improve and streamline management of this condition should be made3.  
 
Long-term RRT by dialysis is dependent upon adequate vascular access. The 
placement of an arteriovenous fistula or graft has a lower mortality rate compared to 
dialysis via a central venous catheter, both when done pre-emptively and creating the 
access early to prevent catheter use, and when converting a patient from a catheter to 
a vascular access conduit5.  
 
Another important factor to consider is cost. These patients place an enormous 
burden on the healthcare system. ESRD and haemodialysis patients consume 
proportionally far more of the yearly spend than they make up in terms of patient 
population. In 2010, the treatment of ESRD cost Medicare, the primary funder of 
treatment of ESRD in the USA, more than $25 billion6. In these patients, the most 
expensive way to deliver dialysis is by catheter. These costs are only equivalent to 
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vascular access when the access requires multiple procedures to keep it patent. 
Therefore, making access as efficient as possible is an important goal for both patient 
care and economic reasons7. 
 
2.2 Haemodialysis 
Haemodialysis is the removal of water and solutes from the patient by using 
diffusion and convection. Diffusion is the movement of solutes across a 
semipermeable membrane along a concentration gradient. Clearance of a solute via 
diffusion is dependent on many factors, including molecular weight, electrical 
charge, fluid concentration gradient, type of dialysis membrane and blood and 
dialysis fluid flow rates. Convection refers to the movement of solvent and dissolved 
solutes across a semipermeable membrane along a hydrostatic pressure gradient. 
Ultrafiltration is the convective movement of water across a semipermeable 
membrane8. 
 
Haemodialysis is the combination of these principles to clear the patient’s blood of 
toxic products of metabolism. The blood is pumped via an extracorporeal circuit, 
from the patient using the vascular access into the “arterial side” of the circuit. The 
blood flows through a pressure monitor into the dialysis machine. This machine 
consists of a dialyser, which is in effect a semipermeable membrane with two 
different fluid circuits flowing in opposite directions on either side, i.e. blood and 
dialysis fluid. Machine characteristics differ in terms of membrane type, surface 
area, permeability characteristics and other components. The blood leaves the 
dialysis machine via the “venous side” of the circuit. This flows through a pressure 
monitor and clamp mechanism, and back into the patient via the “venous needle” in 
the vascular access. The volume of fluid to be removed can be regulated by 
controlling flow rates of the dialysis fluid8.  
 
Different types of haemodialysis utilise varying levels of diffusion, convection and 
ultrafiltration, depending on the requirements of the patient who is receiving 
dialysis8. However, all machines require a minimum flow rate of blood into the 
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machine of 300–500 ml per minute. In the short term, this can be provided by using 
indwelling catheters in the central venous system. However, in the case of long-term 
dialysis, it is mandatory to get permanent vascular access to achieve this high 
volume blood flow, all the while minimising trauma and complications. 
 
2.3 Vascular access 
2.3.1 Central venous access 
Central venous access can be achieved by indwelling catheters, either temporary 
non-tunnelled catheters, or more permanent catheters tunnelled under the skin with a 
cuff for tissue ingrowth. Temporary catheters are at higher risk of both infection and 
being dislodged9. The catheters insert directly into the central veins (internal jugular, 
subclavian and femoral), which provide sufficiently high volume flows to perform 
adequate dialysis. The “arterial side” and the “venous side” of the circuit are 
provided in a single catheter, either by a split tip or staggered holes in the catheter. 
These catheters are associated with significant morbidity and should not be regarded 
as a permanent access solution unless all other access options are exhausted10.   
 
2.3.2 The arteriovenous fistula 
Haemodialysis was initially described in the acute setting in 1943 by Willem Keolf, 
a Dutch physician. A variety of manoeuvres to gain vascular access were tried, 
including arterial cutdowns, problematic in a heparinised patient, and direct needling 
of the arteries and veins. The vessels would then be ligated after a single use, which 
was not a sustainable practice in the longer term11. Attempts to provide multi-use 
access with rubber tubing left in situ failed because they clotted quickly and caused 
significant complications12. These procedures were also technically difficult and 
time-consuming to perform. It was only later, in the United States, that the first 
description of reliable vascular access emerged. In 1960, the report of the first 
patient to receive chronic haemodialysis was published. Mr. Clyde Shields was 
dialysed via an arteriovenous shunt made of Teflon, called the “Scribner shunt”. Two 
tapered Teflon cannulae were inserted into the radial artery and adjacent cephalic 
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vein, and connected externally by a curved Teflon tube. This was later changed to 
silicon rubber. Remarkably, this patient went on to survive (albeit with a transplant) 
for a further 11 years. Not surprisingly, these shunts – although a vast improvement 
on prior techniques – had numerous complications of their own. They fell out, 
clotted and became infected very easily11. 
  
At a similar point in time, two physicians had begun to contemplate the same 
problem of good-quality reusable dialysis access. James E Cimino and Michael J 
Brescia, physicians in New York, had been working on the problem of access. In 
1965, in conjunction with general surgeon Dr. Kenneth C Appell, the eponymous 
fistula procedure was performed. Published a year later, the classic Brescia-Cimino-
Appell fistula involved a side-to-side anastomosis of the radial artery and cephalic 
vein13. This would later be modified to the procedure currently performed today, 
which involves an end-to-side anastomosis of vein to artery via a 5–6 mm 
arteriotomy.  
 
The technique described above has been modified for use in other anatomical 
locations. Most commonly, these involve using the brachial artery as arterial supply, 
and then the most convenient and best-quality vein for an end vein to side arterial 
anastomosis.  
 
The vein serves as the access conduit for the dialysis to take place14. This arterio-
venous fistula can be located on the upper limb in any of three well-described 
positions, dependent on the patency of the vein and patient anatomy. Potential sites 
include the “snuffbox” fistula, located at the anatomical snuffbox, or at the wrist, or 
a looped fistula located more proximally with transposition of the vein to give length 
for needling7. Another commonly used site is the antecubital fossa. Groin fistulae are 
described but far less common7. Fistulae are named according to the artery and vein 
being used, e.g. radiocephalic, brachiocephalic or brachiobasilic. The vein conduit 
can either be left in situ or transposed. Transposition implies dissection of the vein 
from surrounding tissue to either relocate it in the arm or to bring it more 
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superficially to allow for easier needling during dialysis15. The fistula requires a 
period of maturation, usually about four to six weeks, before it can be used for 
dialysis. Criteria for maturity can be assessed clinically and radiologically, and the 
National Kidney Foundation–Dialysis Outcomes Quality Initiative’s (NKF-DOQI) 
“rule of 6” is generally applied. This means that the flow rate should be greater than 
600 ml/min., the vein diameter greater than 6 mm and the conduit should be less than 
6 mm below the skin surface16. However, functional maturity is achieved only when 
the fistula is first used for successful dialysis. Although the first published series of 
radiocephalic fistulae had an excellent maturity rate (12 of 14 matured for use), in 
later years distal fistulae have proven to be more challenging, with a failure to 
mature rate of up to 66%17. There are a number of factors which have been shown to 
be predictive of failure of maturation in AVF, including age greater than 65, female 
gender, obesity, peripheral vascular disease, diabetes, cardiovascular disease and 
wrist location of the fistula. Other important considerations include vein diameter of 
less than 2 mm and poor vein distensibility16. Although the Canadian and American 
guidelines recommend a radiocephalic fistula as the first procedure of choice, there 
is strong support for using an upper-arm fistula first in certain high-risk patient 
subsets, e.g. obese females and diabetics with documented peripheral vascular 
disease17.  
 
If the anatomy at the wrist is unfavourable, or patient factors are unsatisfactory, or 
the patient has had a previous radiocephalic fistula, the next step is to proceed to an 
upper-arm fistula. The brachiocephalic fistula involves an anastomosis between the 
brachial artery and cephalic vein. Because of the vein’s lateral position, and often 
minimal dissection, it is the procedure of choice in the antecubital fossa15. The 
second choice is the basilic vein7. The downside of this is the need for transposition 
of the vein, which requires either a more extensive and lengthy procedure, a longer 
wound or the need for a 2-stage procedure7.  
 
Clinically significant arterial steal should also be considered when placing the AVF, 
but it is a relatively uncommon complication. Twenty percent of patients with upper-
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arm access will have symptoms of arterial steal (diversion of arterial flow into the 
fistula, limiting arterial flow to the extremity), but only 4% will have severe enough 
symptoms to require intervention, which most commonly involves ligation of the 
fistula18. The risk can be minimised by placing the anastomosis as distally as 
possible.  
 
It is generally accepted that AVFs are superior to the use of vascular grafts15, 19. The 
first NKF-DOQI guidelines published in 1997 encouraged placement of autogenous 
AVFs2. The Fistula First Breakthrough Initiative (FFBI) in the United States in 2003 
found that by far the majority (up to 80% in some areas) of prevalent dialysis access 
was via grafts5. It was felt that performing new procedures as AVFs wherever 
possible would result in a significant cost saving to healthcare in the US20. A similar 
initiative, the CIMINO initiative, was begun in the Netherlands21. However, as this 
programme grew in the US, an unexpected finding appeared: the FFBI showed that 
there has been a significant increase in the use of AVFs – from 32% in 2003 to 60% 
in 201222. The increase in use of AVFs has been associated with an increased 
primary failure rate. a systematic reviewnoted that before 2000, AVFs had a primary 
failure rate of 10% to 24%. However, in recent years this has increased to up to one 
third of all fistulae. Forty percent of all AVFs had either failed to mature completely 
or required at least one intervention to remain patent23. Other reviews have shown 
that, as the proportion of ESRD patients over 65 have increased, there have been 
higher primary failure rates and poorer primary patency rates10. These studies have 
challenged the recommendation that the forearm fistula always be the first procedure 
of choice, since it has a higher primary failure rate than an upper-arm procedure23. 
The challenge is to improve the AVF technique to lower primary failure rates and 
loss of patency while keeping the advantages of an autogenous procedure.      
 
2.3.3 The arteriovenous graft 
The “Scribner shunt” is now obsolete shunt technology. In principle, the technique of 
arteriovenous grafts remains the same, with the use of synthetic graft material 
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providing a conduit between the artery and vein. The graft can then be needled 
directly for dialysis.  
 
The choice of graft, both in terms of material as well as location, has evolved over 
the years since 1960. The materials used have changed from Teflon to Dacron, and 
more recently to the PTFE (polytetrafluoroethylene) graft used today. Human 
umbilical vein and bovine graft have also been used and abandoned12. Graft location 
has also changed, with use of the femoral artery and vein now considered a position 
of last resort after all other access attempts have failed. Novel ideas such as the 
“button” – a carbon-sealed access plug attached to the vessel with PTFE – have also 
not shown any longevity12. 
 
The current practice is an attempt to mimic autologous vein access as far as possible. 
Implantable grafts are fully internalised and follow a looping course, from distal 
artery to proximal vein. The key is the choice of material, which should be easy to 
handle, non-aneurysm-forming, as well as easy to remove if infected or thrombosed. 
This role is currently filled by the PTFE graft. This material can be modified to be 
straight, tapered or curved, and diameters range from 4 mm to 8 mm24. PTFE can 
also be layered to include self-sealing elastic layers post needling (GORE® 
ACUSEAL). Current practice globally is to use ePTFE (expanded 
polytetrafluoroethylene) grafts7. 
 
AVGs are positioned according to similar principles as those applied to AVFs. They 
are preferentially placed distally in the forearm first, and then proceeding more 
proximally until more atypical sites are considered. They can be placed in a straight 
or looped configuration, and are attached to the artery distally and the vein 
proximally. Common  sites include the brachial artery to cephalic vein and brachial 
artery to the more proximal axillary vein. If these fail, more atypical sites include 
femoro-femoral and axillary-axillary arteriovenous necklace grafts across the chest7. 
Current AVGs are entirely covered by skin and are needled in the same manner as 
AVFs. Distal placement of the arteriotomy is an attempt to limit the phenomenon of 
arterial steal18. Graft shape can be straight (6–8 mm diameter) or tapered (4 mm–7 
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mm). However, there is no evidence that tapering of the graft improves patency 
rates, despite the theory that it would alter the rheology and therefore minimise 
stenosis and graft thrombosis. It was felt that decreasing shear stress by changing 
flow geometry would decrease intimal hyperplasia and therefore graft stenosis. Other 
promising innovation to minimise graft thrombosis and stenosis, such as venous 
cuffs on the grafts, did not show any benefit in human trials24. 
 
AVGs provide a valuable alternative option in patients with ESRD who require 
haemodialysis, but whose anatomy is not amenable to an AVF, because there is no 
suitable vein to be found, as they all have been used in previous access attempts, or it 
is felt that the risk of complications was too high25. AVGs are often quicker and 
easier to perform – there is no concern about maturation and they are quickly 
available for dialysis. However, long-term patency is a problem. A recent systematic 
review found that when primary failure was excluded, AVFs had a pooled primary 
patency rate at one year of 60%, and 51% at two years23. In comparison, AVGs had 
primary patency rates at one year of only 40% to 54%, and at two years of 18% to 
30%2. The secondary patency rates range from 59% to 65% at one year, and 40% to 
60% at two years. In direct comparison of the two choices, pooled results found that 
an AVG was three times more likely to need an intervention and 3.8 times more 
likely to need a thrombectomy than an AVF5.  
 
2.4 Failure of dialysis access 
Failure of dialysis access can be separated into two categories – primary failure, 
when the access never matures for cannulation, and secondary failure, when there is 
loss of patency once it has begun working. Primary failure, or a fistula that is never 
used for dialysis, is perhaps more accurately referred to as early dialysis suitability 
failure (if no procedure has been attempted to mature the fistula), or late dialysis 
suitability failure (if, despite radiological or surgical attempts at intervention, after 
six months the fistula is still not available for dialysis)14. However, in literature the 
term “primary failure” is taken to mean a fistula that never fulfils criteria for use for 
dialysis26.  
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Primary and secondary patency rates are used to define how long fistulae work for, 
with and without intervention. Primary or unassisted patency is the length of time a 
fistula remains functional until the first intervention, which could be endovascular or 
open. It is often quoted as percentage of conduits that are patent after a period of 
time, e.g. at six months or one year. Secondary patency is the length of time a fistula 
remains patent – from initial intervention until access abandonment. It includes any 
number of procedures to restore patency and, like primary patency, is quoted as a 
percentage of access conduits that are patent after a specific time period, e.g. one or 
two years14.  
 
The causes of primary failure are somewhat ill-defined. There are factors that 
increase the likelihood of failure, e.g. diabetes, location of fistula, age of the patient27 
and the diameter of the artery and vein being used16. However, the 
pathophysiological process that leads to fistula failure is not clearly understood. In 
2008, some early research on primary failure showed that neointimal hyperplasia 
was not just a cause of later stenosis of the access, but could also be demonstrated in 
juxta-anastomotic stenosis of primarily failed access28. Although the precise 
mechanism for development of the stenoses is not understood, there are techniques 
available to treat them. Balloon angioplasty has been shown to be effective, with a 
98% success rate in one study, which reduced stenosis to less than 20% of total 
conduit size19. 
 
Another cause of primary fistula failure is the presence of accessory veins. The 
cephalic vein can often have more than one draining accessory vein. This is a normal 
anatomical variant, but can cause problems with regard to fistula maturation19. The 
accessory vein decreases the flow in the fistula vein, and thus diminishes chances of 
maturation because of the decreased pressure and flow. Ligation of the accessory 
vein is a simple procedure that is very effective at salvaging a non-maturing fistula, 
with up to a 100% success rate27. The secondary patency of these fistulae, once 
matured, is similar to that of fistulae that achieved maturation without intervention. 
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The procedures required to effect maturation have a low complication rate, and so 
should be attempted if at all possible27. 
 
In an attempt to move away from costly surgical procedures, there have been 
attempts to treat primary fistula failure medically. For example, in primary fistula 
failure due to thrombosis, two anticoagulants have been tried to improve primary 
failure rates. Unfortunately, although there was a reduction in the number of 
thrombosed fistulae, there was no effect on the number of fistulae which could be 
used for dialysis, i.e. primary functional patency29.  
 
Late vascular access failure is generally the result of venous stenosis in both grafts 
and fistulae30. In AVGs, the stenosis is usually at the graft-vein anastomosis. In 
AVFs, it is most commonly juxta-anastomotic31, i.e. at the first part of the vein to 
experience arterial flows and pressures. These stenoses form on the basis of 
neointimal hyperplasia, which involves migration of smooth muscle cells and 
myofibroblasts, and laying down of increased extracellular matrix31. Precisely how 
the hyperplasia is initiated remains unclear, but fluid dynamics impact on the 
development and worsening of intimal hyperplasia24. Whether the stenosis was 
present prior to fistula creation, and only becomes clinically significant later on, is 
difficult to determine, even if preoperative imaging is performed. This is due to the 
change in flow volume and haemodynamics in that vessel. However, it is well 
established that venous stenosis must be treated and monitored to prevent thrombosis 
and loss of access32.  
 
The benefits of surveillance are less well defined. The Society of Vascular Surgery’s 
clinical guidelines support the use of surveillance of vascular access26. Should the 
surveillance show stenosis of more than 50%, DOQI guidelines indicate that balloon 
angioplasty should be performed in order to reduce the stenosis to less than 30% of 
the lumen15. Failure to treat these stenoses, whether venous, arterial or juxta-
anastomotic, will result in fistula thrombosis, and this is far more difficult to treat. 
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It is unclear whether the treatment of a thrombosed fistula is better with closed 
thrombolysis (pharmacological and/or mechanical33) or with open thrombectomy. It 
is important that any stenoses found are treated as well. However, because of the 
high secondary patency rates, salvage of a thrombosed fistula is worthwhile32. There 
has been a substantive growth in novel therapies to minimise and treat access 
thrombosis, such as drug-eluting stents, grafts, and wraps, and endovascular 
radiation. These are all in the laboratory phase and have not been tried in clinical 
practice31, 34. 
 
2.5 Imaging of vascular access 
2.5.1 Duplex ultrasound 
Duplex ultrasound is widely used to image AV access. It is non-invasive and 
includes imaging of the vessel as well as information about flow within the fistula. It 
is a combination of pulsed Doppler spectral analysis, B-mode ultrasound and colour 
Doppler imaging35. Duplex ultrasound for diagnostic purposes in dialysis access was 
first validated in the late 1980s, when it had been available commercially for only a 
few years. It was recognised that an imaging modality that could non-invasively 
assess both anatomical and flow information would be valuable in the setting of 
dialysis access. The technique used included mapping of the entire access using 
linear high-frequency probes for b-mode or colour Doppler vessel imaging and flow 
rate measurement, and pulsed wave Doppler velocity spectra measurement for 
stenosis classification (i.e. more or less than 50%)36. When compared to 
angiography, which is the gold standard, it was found that duplex ultrasound had an 
accuracy of 96% when diagnosing efferent vein stenoses (sensitivity 95%, specificity 
97%). The accuracy of diagnosing anastomotic stenoses in radiocephalic fistulae was 
less at 81% (sensitivity 79%, specificity 84%)37. Subsequent studies found a lower 
level of accuracy, with approximately 80% sensitivity and specificity36, which was 
still accurate enough to make duplex ultrasound the first imaging investigation of 
choice, as well as a useful adjuvant to other imaging38. It is currently recommended 
in the NKF-DOQI initiative that duplex ultrasound be used in the surveillance of 
dialysis access. However, the evidence for this recommendation is weak26. 
Flow velocity measurement in haemodialysis access using 4D MRI Downs J 
 
20 
Nonetheless, surveillance with a combination of duplex ultrasound and physical 
examination is recommended according to the algorithm in the DOQI initiative36. 
The most important caveat to the use of duplex ultrasound is that its results are 
operator dependent. Most errors result from incorrect technique by the technologist, 
and a small change in technique can have a large change in results35. For this reason, 
it is encouraged to only use an accredited vascular laboratory for dialysis access 
surveillance. Duplex ultrasound of dialysis access is noted to be particularly difficult, 
due to vessel tortuosity and high-peak systolic velocities causing increased flow and 
artefact, especially at the arterial anastomosis36. Another limitation of duplex 
ultrasound diagnosis is that the access may be failing due to central vein stenosis, 
which duplex ultrasound does not easily detect. This should be borne in mind when 
reviewing results.  
 
2.5.2 Contrast fistulography 
Contrast fistulography is currently considered the gold standard of fistula imaging36. 
The technique involves cannulation of the venous outflow tract and contrast 
injection. If this does not provide adequate arterial imaging, a cuff can be used to 
obstruct venous outflow or a guide wire and catheter advanced down into the artery 
to inject the contrast. The images should be obtained in multiple planes to limit 
obscuring tortuous vessels and aneurysms. These are then reviewed after digital 
subtraction. The major advantage of digital subtraction angiography (DSA) over 
non-invasive imaging techniques is that it allows for simultaneous intervention. This 
limits the number of procedures, and therefore the cost of failing access salvage. It 
also allows for imaging of both the entire tract as well as the full venous outflow, 
permitting diagnosis of central venous stenosis. It has been suggested that when 
performing (or planning) percutaneous intervention for failing fistulae, full imaging 
of the outflow tract should always be performed, as central stenosis is too often 
missed by duplex ultrasound39. 
 
The limitations to fistulography are numerous. It is invasive and has complications 
that include access rupture and access thrombosis. It requires the use of ionising 
radiation, which must be borne in mind, as these patients often require multiple 
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procedures over the years to maintain access patency (Dixon et al. 2009). It also 
requires the use of intravenous contrast, which would be deleterious to whatever 
residual renal function there is. For these reasons, it is seldom used in isolation, and 
should be considered an intervention modality rather than purely an imaging 
modality39.  
 
2.5.3 CT fistulography 
CT angiography, especially since the advent of multislice helical CT scanners, 
provides very good quality images of arteries40. The faster acquisition times and 
increased number of images per unit area help to provide detailed images of the 
vessels of interest. It has not been used widely in terms of dialysis imaging. 
However, in one small study it showed equal sensitivity and specificity to DSA 
when diagnosing stenoses41. Unfortunately, CT fistulography combines the 
disadvantages of MRA and DSA, in that it requires venepuncture (against the 
principles of access site conservation of the DOQI) and the use of intravenous 
contrast. Furthermore, it uses ionising radiation. However, unlike DSA, it does not 
provide the option to perform intervention, which is the benefit that outweighs the 
risks of intravenous contrast and radiation.  
 
2.5.4 MR angiography 
Magnetic resonance angiography (MRA) is another non-invasive imaging technique 
that has not been studied extensively, but could be used as an adjuvant imaging 
technique. Small studies have shown that it is sufficiently accurate when compared 
to contrast fistulography42-44. There have also been attempts to use 2D CINE PC in 
measuring flow in dialysis access, which, although limited by the early stages of 
MRI software, showed good reproducibility and that such measurements were 
feasible45, 46. 
 
Like CTA and duplex, it is non-invasive, but unlike duplex, it is not operator 
dependent. Unlike CT, it does not require the use of ionising radiation. However, 
some techniques require intravenous gadolinium contrast, and this has led to the 
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development of nephrogenic systemic fibrosis, which is a rare complication. This 
can present with limb oedema, muscle weakness and fibrosis, including the 
diaphragm and oesophagus, and skin lesions such as cutaneous papules and plaques. 
The only consistent link is that it occurs in patients with poor renal function and is 
strongly associated with gadolinium administration47. This must be taken into 
account when considering contrasted MRA in patients with dialysis access, who by 
definition have poor renal function. MRA is costly, both in terms of price and the 
time it takes to perform the examination42. It is described  for second-line imaging 
after duplex ultrasound, or if there was a non-diagnostic segment on DSA44. 
 
2.5.5 4D flow-sensitive MRI 
Magnetic resonance imaging (MRI) generates images through the application of 
three magnetic fields: the main external field, magnetic field gradients and an 
applied oscillating field. The external field aligns all the protons of the image subject 
within its field (protons are hydrogen atoms and, because of the high proportion of 
hydrogen in human cells, it is their signal that generates an MRI image). The applied 
gradients turn the external field on and off in a linear fashion, changing the 
resonance of the protons. The placing of a coil provides the final oscillating or 
radiofrequency field, which forces the protons to resonate and produce a signal. A 
mathematical algorithm called the Fourier transform is then used to convert the 
signal into an image48.  
 
The application of gradients and fields form a pulse sequence that is specific to the 
type of tissue that is being imaged. These pulse sequences are designed to provide 
more or less weighting to different types of relaxation (the loss of the longitudinal 
and transverse magnetisation provided by the magnetic fields), i.e. T1 and T2. This 
permits very fine differentiation of tissues, and provides the soft tissue detail that 
MRI is so well known for. Imaging of blood puts more emphasis on the T2 signal48. 
  
4D MRI captures images using phase contrast technology. A bipolar gradient is 
applied between the excitation pulse and the readout. Two images are collected and 
compared. The moving particles acquire a different phase along the applied gradient, 
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and can therefore be differentiated from the static particles. The static particles (and 
image of static tissues) are subtracted, and the final image is generated. The 
gradients are applied according to expected velocities of moving particles (in our 
case, blood). The change in phase also allows for the velocity of these moving 
particles to be calculated. These images are acquired in three directions, and cover 
the entire volume of the imaged area. The addition of ECG gating means that these 
images are said to be collected in “four dimensions”, three spatial dimensions and 
time49. 
  
This was initially used in larger vessels such as the aorta, and subsequently in 
progressively smaller vessels as image acquisition and data processing technology 
improved. When 3D phase contrast became available, it permitted analysis of more 
complex flows49, a hallmark of dialysis access on duplex ultrasound36. 
 
One of the advantages over previous 2D CINE PC MRI is that because it gathers the 
same velocity data over the whole 3D volume, analysis of a specific area can be 
performed at any point throughout the volume without risk of plane misalignment, 
and therefore incorrect results. It has been found to be both accurate and reliable, 
even though pulse sequences and data analysis tools are constantly being updated50. 
For example, 4D MRI, when used to image stenosed renal arteries, provided data 
about haemodynamically significant stenoses that correlated with invasive pressure 
measurements in animal studies51. It not only provided imaging from the scans 
themselves, but the data could also be used to cross-validate and enhance 
computational flow dynamic models, which are proving to be useful in the field of 
vascular flow dynamics52. Limitations in this technology include the length of time 
taken to scan the required volume, but this is improving53. 
 
2.6 Computational flow modelling 
The science of computational flow modelling is based on the application of the 
Navier-Stokes equations, which have changed greatly since first inception. They are 
a set of equations designed to predict the actions of a single-phase fluid under certain 
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predetermined conditions54. These equations were initially used in settings such as 
aircraft design (air flow), but as access to high-power computing has improved, they 
are being applied more widely across many fields, including that of haemodynamics. 
This means that, by using these equations, one can predict the path, speeds and shear 
stresses applied by a fluid in a predefined area, such as a dialysis fistula or graft.  
 
In order to calculate predicted flows, a set of boundary conditions must be applied. 
These include the type of fluid and the conditions at the physical edges of the area to 
be modelled – the flow rate, volume of the area and pressures.. The more accurate 
the boundary conditions, the better the predictive accuracy of the fluid dynamics. 
These boundary conditions are  determined from available information, either 
estimated or measured55. 
 
Previous studies have attempted to determine if changing specific anastomotic angles 
will change haemodynamic conditions at anastomotic sites, and thereby decrease 
fistula failure55. This information was calculated using  boundary conditions which 
were either estimated or measured using a variety of imaging techniques such as 
duplex Doppler and digital subtraction angiography56, 57. These studies provided 
promising results,suggesting that an alteration of anastomotic angle could change the 
wall shear stress or oscillatory shear stress index, which may decrease intimal 
hyperplasia55. However, it must be remembered that flows in a dialysis access fistula 
or graft are far more complex than flows in a vascular arterial bypass graft (the blood 
flow rate alone is 5–10 times higher), and therefore the effects of changes in 
technique are far harder to predict58. Previous studies have shown a correlation of 
results from CFD modelling and imaging using duplex Doppler59. 
 
4D MRI could therefore fulfil two roles: it could provide accurate boundary 
conditions for the computational modelling, which would allow high-quality model 
building and data generation, and also, by using  particle tracking image generation, 
flow rate measurement and wall shear strength calculation, it could provide 
validation for those calculations. However, before this can take place, imaging 
protocols must first be designed to see if it can be used in these difficult vessels.  
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CHAPTER 3  
Journal ready manuscript 
  
3.1 Introduction 
The incidence of end-stage renal disease (ESRD) in sub-Saharan Africa is 
increasing. In 1994, there were 70 people per million population (pmp) receiving 
renal replacement therapy. In 2012, there were 164 pmp1. The treatment of ESRD, 
while including managing causative diseases and complications of the ESRD, 
requires renal replacement therapy (RRT). The ideal way to do this is via a renal 
transplant2. The alternative option for replacement therapy is dialysis, which is able 
to fulfil some functions of the failed kidney. Dialysis can be provided by two 
methods: either by using machines to perform the filtration function of the kidney on 
blood circulated through them (haemodialysis), or to use the patient’s peritoneal 
membrane to act as a filter to remove dialysates from the blood (peritoneal dialysis).   
If peritoneal dialysis is not an option, ESRD patients are placed on a haemodialysis 
programme.  
 
In South Africa, the current renal transplant rate is 4.7 pmp, far lower than the 164 
pmp receiving RRT3. Even in the USA, the median time to renal transplant is 1.71 
years4. Efforts are made to minimise time on haemodialysis programmes and 
improve access to transplants, but the current reality is that the average patient can 
spend (depending on various factors) months to several years on haemodialysis.  
 
Haemodialysis requires high flow access to the patient’s circulating blood volume5. 
The ideal access should be safe, cause minimal complications, have a long usable 
period, be usable early, be comfortable and cosmetically acceptable for the patient, 
economical, and not require repeated interventional procedures for the patient6. 
Currently, access is either via central large bore vascular catheter, or preferably 
arteriovenous fistula (AVF) or arteriovenous graft (AVG)7. These are generally 
peripheral procedures, placed most often in the upper limb, and provide a sufficiently 
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high blood flow rate in a smaller peripheral vessel to allow adequate haemodialysis 
to take place. Both of these options are far from perfect. The biggest complication of 
peripheral access is failure, either of maturation or thrombosis8, 9. As each patient has 
only limited sites suitable for AVF or AVG creation (due to variations in patient 
anatomy and complications from previous lines and procedures), every attempt 
should be made to make each access AVF or AVG the last one for that patient.  
“Every failed vascular access is a nail in the coffin of an ESRD patient.”  
– Prof D Kahn 
 
In order to optimise access performance, information about the structure of the AVF 
or AVG as well as haemodynamics of the flow through the access is required. A new 
type of magnetic resonance imaging (MRI), 4D flow-sensitive MRI, makes use of 
existing MRI machines and new analysis software to generate data – not only about 
structure, but also haemodynamics10. If the imaging provides enough detail in terms 
of flow rates and directions, it will be used to help build models of dialysis access. 
The models can then be used to see if alterations in technique or materials would 
improve patency rates, decrease maturation times and decrease complications.  
However, 4D MRI has never been used on such distal vessels, or on such complex 
flows before, and has never been used to provide data for modelling on such vessels. 
The following study attempts to pilot this technique in such vessels to see if such a 
project would be feasible.  
 
3.2 Methods 
The study was approved by the UCT Human Research Ethics Committee (HREC 
REF719/2013). The patient information sheet and informed letter of consent are 
attached in the appendices. A total of 14 participants were included in the study. The 
demographic data, including the age, gender and cause of ESRD, as well as type and 
age of access were recorded. Racial demographics were not recorded.  
 
The control group consisted of six young, healthy volunteers who were recruited 
from the general public. They had no history of significant vascular or medical 
conditions, and no attempt was made to control for relative hyperaemia after 
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exercise, fluid consumption or other variables. There were eight patients with ESRD 
on dialysis included in the study. Scans on dialysis patients were performed at least 
six hours after dialysis in an attempt to control for the wide variation in fluid 
balances in these patients. Access patients were recruited from the chronic 
haemodialysis programme at Groote Schuur Hospital’s renal unit.  
 
All vascular access in these patients were created as surgical procedures by the 
Groote Schuur transplant unit. The operations were performed under either local or 
general anaesthesia. The upper limbs were examined and a suitable vein identified 
by clinical examination and ultrasound. If there was no suitable vein for an AVF, the 
decision was taken to perform an AVG. For upper-arm AVF, the skin incision was 
made in the antecubital fossa, and the vein gently dissected free of surrounding 
tissues to gain as much length as possible. Any visible accessory branches are 
ligated. The brachial artery was then dissected and controlled with vessel loops. The 
vein was ligated and divided as distally as possible, and anastomosed to the brachial 
artery using 7/0 nonabsorbable sutures.  
 
The insertion of the AVG involved the anastomosis of a 6 mm PTFE graft between 
the brachial artery in the antecubital fossa distally, and the axillary vein in the distal 
axilla proximally, via a tunnel subcutaneously on the lateral aspect of the upper arm. 
The anastomoses were made with 6/0 nonabsorbable sutures.   
 
All study subjects were informed as to the aims and methods of the study. Informed 
consent was taken and included, but was not limited to full consent about the MRI 
scanner and the presence or absence of contraindications to a MRI scan. MRI scans 
were performed at Groote Schuur Hospital after hours in the Siemens Magnetom 
Symphony 1.5T MRI Scanner. The MRI scans were performed between March 2013 
and November 2014. A standard 30 cm body coil was used, and the area scanned 
was dictated by the position of the coil. This was placed over the upper-arm dialysis 
access by the assisting MRI radiographer. The area scanned was limited by the size 
of the coil. All scans were performed with simultaneous ECG recording, providing 
the data for cardiac gating.  
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The MRI acquisition settings were optimised throughout the study. They were 
initially derived from the 3D MRI velocity mapping package developed by Markl et 
al.  
 
The scans were collected and stored anonymously. They were analysed with the 
following points of interest selected: the brachial artery proximal to the 
arteriovenous anastomosis, the anastomosis itself, and the outflow in the fistula. 
 
  
Figure 1: MRI slice from AVF 3 – determined point of interest is the pitch black 
cross-sectional area over the vessel.  
 
The images were pre-processed and the data analysis undertaken as part of other 
related postgraduate research projects. Software used for pre-processing and analysis 
included MathWorks’ MATLAB image processing toolbox and previously 
developed pre-processing and visualisation GUI and code11, Super Tool v026, as 
well as VeloMap Tool12 and flow Tool13. The images generated numerical values, 
giving flow velocities at the determined areas of interest along the vessel. 2D scans 
generated axial velocities at designated areas of interest on the MRI slices, and the 
data generated from the 3D time-resolved scans (or 4D) was then processed for 
particle tracking. The variables used in this study were velocities and flow rates, 
measured in centimetres per second (cm/sec) and millilitres per minute (ml/min.) 
respectively.  
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The 3D post-processing programme generated data in three axes viz x, y and z, with 
z being the axis of “forward” or axial flow. Each point of interest was divided up 
into “voxels”, which are areas of the scan measuring 1.56 x 1.56 x 2 mm, and 
velocities were calculated within these areas. Positive numbers indicated flow in the 
expected direction (i.e away from or returning to the heart). The z-axis data was used 
to calculate the mean flow velocity and volume.  
 
Unfortunately, some scans did not provide usable data. The results from volunteers 
one and two were not included as they were early attempts at scan protocols, and the 
settings did not provide usable data. The scans from volunteer five were localised on 
the wrong vessels, and therefore the results were not relevant to this study. AVF 1 
had incorrect placement of the scan field, and therefore these results were also not 
usable. Those scans were repeated and the results were presented under AVF 4. AVF 
2 was initially misclassified, and the results were given under AVG 3. AVG 3 only 
had brachial artery and graft midpoint data due to the initial misclassification, which 
resulted in errors in placement of the MRI arm coil. Similarly, results for AVG 1 
were not available due to the software not being able to unwrap data correctly. Some 
of the results from AVF 3 and 7 and AVG 2 and 3 did not unwrap correctly using the 
software, and were therefore not available.  
 
 
 
 
     
    
 
     
 
 
 
Total participants n = 14 
Volunteers n = 6 ESRD patients n = 8 
In study n = 3 
Excluded n = 3 
Unusable scans 
Excluded = 1 
Reclassified /rescanned n = 2 
In study n = 7 
Complete data n = 3 
Incomplete data n = 4 
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Duplex Doppler ultrasound scans were performed on two patients to confirm that the 
velocities generated by the software were in the correct range. The duplex Doppler 
ultrasound scans were performed just prior to MRI scanning. The first duplex on 
AVG 2 was performed by a dedicated vascular ultrasonographer on the Toshiba 
Aplio 400 machine, whereas the second ultrasound was performed on a portable 
cardiovascular ultrasound system (Vivid I, GE Healthcare) by a different trained 
team member.   
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3.3 Results 
Patient data 
There were six healthy volunteers in the study, consisting of four males and two 
female, with an age range of 23 to 29 years. The ten ESRD patients included six 
females and four males, with an age range of 22 to 55 years. The original causes of 
ESRD included hypertensive nephropathy, chronic glomerulonephritis, and 
nephrotic syndrome. The age of the dialysis access varied from 12 to 15 months old. 
The ESRD patients included five with an AVF and two with a PTFE AVG.  
 
Haemodynamics 
Volunteers 
The flow velocities in the brachial artery in the healthy volunteers ranged from 5.8 
cm/sec to 6.2 cm/sec. The flow rates in the brachial arteries of the volunteers ranged 
from 25.8 ml/min. to 52.1 ml/min.  
 
 
Figure 1: Flow rate and flow velocity through the brachial artery in healthy 
volunteer five. 
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Figure 1 is a representation of the flow through the defined point of interest in the 
brachial artery of volunteer five. The time in milliseconds on the x axis is provided 
by the ECG gating, and the changes in flow and velocity correlate with the cardiac 
cycle. The flow through the point of interest very closely resembles the cardiac 
cycle, with a large increase of flow rate and velocity in systole, and a much smaller 
diastolic peak later in the cycle. 
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ESRD patients 
The average flow rates and velocity generated using MRI data in the ERSF patients 
and healthy volunteers in the various regions of interest are shown in Tables 1 and 2 
respectively.  
 
Flow rate 
 Arteriovenous fistula (AVF) Arteriovenous 
graft (AVG) 
Volunteer 
03 04 05 06 07 02 03 03 04 06 
Brachial 
artery 
?* 2477.0 2186.7 1729.6 2162.5 1431.3 1528.7 52.1 46.3 25.8 
Anastomosis 
Arterial side 
Venous side 
957.0 1857.3 3507.6 ?* – 
 
1158.6 
 
2827.8 
– 
 
660.0 
 
1681.0 
– 
 
?* 
 
?* 
– – – 
Fistula/graft ?* 1967 4398.1 2809.2 787.5 – 698.3 – – – 
Cephalic vein – – – – – – – 10.8 6.9 27.9 
Table 1: Flow rates (ml/min.) in ESRD patients with AVF or AVG, and healthy 
volunteers. 
?* = indicates no result available, either due to poor data unwrapping or incorrect 
coil placement. 
 
Flow velocity 
 Arteriovenous fistula (AVF) Arteriovenous  
graft (AVG) 
Volunteer 
 03 04 05 06 07 02 03 03 04 06 
Brachial 
artery 
?* 85.5 93.2 80.7 95.0 60.1 62.4 5.8 8.5 6.2 
Anastomosis 
Arterial side 
Venous side 
34.3 68.3 22.9 ?* – 
42.0 
67.1 
– 
63.3 
85.0 
– 
?* 
?* 
– – – 
Fistula/graft ?* 10.4 24.7 69.6 15.6 ?* 6.8 – – – 
Cephalic vein – – – – – – – 1.4 4.3 14.2 
Table 2: Flow velocity (cm/sec) in ESRD patients with an AVF or AVG, and 
healthy volunteers.  
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?* = indicates no result available, either due to poor data unwrapping or incorrect 
coil placement. 
 
The flow rates in the brachial arteries of AVF patients ranged from 1 729 ml/min. to 
2 477 ml/min. These were much higher than in the healthy volunteers (25.8 ml/min. 
to 52.1 ml/min.). The flow rates ranged from 957 ml/min. to 3 507.6 ml/min. through 
the arteriovenous anastomosis. Due to the large diameters, these fistulae were still 
able to provide high volume flow, which ranged from 787 ml/min. to 4 398.1 
ml/min. However, the flow velocities in the fistula itself were far lower than in the 
brachial artery, and ranged from 10.4 cm/sec to 69.6 cm/sec. The velocity through 
the anastomosis ranged from 15.7 cm/sec to 68.3 cm/sec.  
 
There was an increased mean flow rate in the brachial arteries of the vascular access 
patients (1 919 + 380 ml/min.) compared to the healthy volunteers (41 + 11 ml/min.). 
There was a similar increased mean flow velocity in the brachial artery of the 
vascular access patients (79 + 14 cm/sec) compared to the healthy volunteers  
(6.83 + 1.18 cm/sec). 
 
The small sample size does not permit true comparison of flow volumes and 
velocities between grafts and fistulae. It is worth noting that, despite their slower 
velocities, the fistulae still managed to carry more than sufficient volume for 
adequate dialysis (>500 ml/min.).  
 
These numbers were averages over multiple cardiac cycles and therefore cannot 
represent the complexity of the haemodynamics in these vessels. However, a closer 
look at the source data that generates the averages mentioned above illustrates the 
complexity of the haemodynamics. Table 3 below shows the maximum and 
minimum velocities collected over 28 time points in the cardiac cycle in the “z axis” 
or forward flow. The wide variations in numbers show how turbulent the flows are, 
both in terms of the difference between each voxel at the area of interest, as well as 
the difference between maximum and minimum flows during the cardiac cycle.  
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Flow velocities in AVF 7 arterial side of the anastomosis, voxel by voxel 
Vz  Vz Vz Vz 
Max Min mean Stddev 
74.16992 -90.234 23.7793 38.16601 
78.44238 -64.770 34.68863 31.0278 
82.88574 -33.837 35.06611 30.16268 
82.03125 -43.579 36.66804 30.91183 
82.54395 -41.015 38.00143 30.57033 
89.72168 -39.648 39.73483 30.86187 
85.62012 -51.782 39.85502 30.15612 
81.00586 -55.371 39.24467 30.45496 
101.001 -72.631 44.13687 41.71875 
122.5342 -130.22 53.41046 55.61971 
142.0166 -175.17 53.82174 73.73747 
161.8408 -164.06 53.20951 70.60018 
125.6104 -218.75 50.15587 66.6831 
134.1553 -128.85 46.75293 59.88894 
129.0283 -190.21 45.78576 58.69188 
120.8252 -139.11 46.8919 54.46475 
108.3496 -161.32 41.97529 48.72214 
102.5391 -122.53 40.97055 43.9936 
88.35449 -47.680 37.58451 34.07297 
83.05664 -61.865 37.4831 35.43361 
92.96875 -152.44 39.23528 44.07499 
96.72852 -110.05 40.8297 45.66434 
101.001 -112.62 43.94531 47.73145 
98.4375 -112.96 44.08428 44.35089 
102.5391 -76.049 43.50586 43.17241 
105.4443 -94.165 42.86546 42.34809 
125.4395 -43.579 44.27209 37.83868 
90.40527 -116.21 40.69073 38.71687 
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Table 3: Z axis (Forward-flow) velocities through each voxel in the region of 
interest of fistula seven – the arterial side of the arteriovenous anastomosis over one 
cardiac cycle.  
 
This was a pilot study, designed to develop an entirely novel method of scanning 
dialysis access. As the pilot proceeded, scan settings and localisation became more 
accurate, which resulted in the generation of more data from each scan.  
 
 
Figure 2: Flow rate and flow velocity through the brachial artery of AVF 4. 
 
The above graph (Figure 2) shows the limited number of data points in an early scan 
in comparison to Figure 3 below. The final scan, AVF 7, generated more areas of 
interest, with more recordable flow rates. It also allowed us to look at flow rates 
across smaller areas in the areas of interest. A single averaged number or table 
cannot convey all the information. Figures 3–6 display flow rate and flow velocity 
versus time over a single cardiac cycle of AVF 7. 
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Figure 3: Flow rate and flow velocity in the brachial artery of AVF 7. 
 
 
Figure 4: Flow rate and flow velocity on the arterial side of the arteriovenous 
anastomosis of AVF 7. 
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Figure 5: Flow rate and flow velocity on the venous side of the arteriovenous 
anastomosis of AVF 7. 
 
 
Figure 6: Flow rate and flow velocity of the fistula of AVF 7. 
 
The graphs in Figures 2–6 should be compared, firstly to each other, and then to the 
graph displaying flow in the healthy volunteer’s brachial artery (Figure 1). The 
marked differences in shape and variability of the graphs indicate the different 
haemodynamics experienced by each area of the access. It is also worth noting how 
different the flows in the different sides of the arteriovenous anastomosis are, despite 
it being such a small area. 
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One of the advantages of the 4D flow-sensitive MRI is that it allows “particle 
tracking”, which is a visual and colour-aided demonstration of flow throughout a 
chosen vessel. Data was collected and encoded in three axes as mentioned above, as 
well as time (using the ECG gating). The scan sequences and software allowed this 
data to then be processed into a visual representation, and the flows in each voxel of 
the starting scan tracked throughout the scan area in the form of “streamlining”. 
Colour is then added to this image to allow easy understanding of both flow 
direction and velocity through the entire scanned vessel14. This could allow us to 
identify areas of interest to focus on to maximise intervention. 
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Figure 7: Example of particle tracking still image from AVF 7 (top); example of 
particle tracking still image showing increased turbulence at arteriovenous 
anastomosis (bottom).  
 
AVF 7’s adequate scan data permitted use of images to perform particle tracking. 
Coloured still image renderings of flow from the video at points of interest 
demonstrate the increased turbulence and flow voids shown in the fistula itself in 
comparison to the brachial artery. The turbulence of the flow through these vessels is 
marked (Figure 7).   
 
Arteriovenous grafts 
Points of interest for velocity and flow calculations in AV grafts were the brachial 
artery proximal to the graft, the artery-graft anastomosis, mid-graft at the same level 
as the brachial artery point of interest, and the graft-venous anastomosis. AV grafts 
were particularly challenging to scan, as the areas of interest were at either end of the 
graft, and difficult to cover with the single MRI coil for the area. As the prosthetic 
graft material cannot dilate (and thus the conduit is narrower than the majority of 
mature fistulae), velocities were expected to be higher to provide similar  to the AV 
fistula.  
Flow velocity measurement in haemodialysis access using 4D MRI Downs J 
 
49 
Brachial artery inflow velocity to the graft ranged from 60.1 cm/sec to 62.4 cm/sec, 
similar to AVF inflow.  
 
 
Figure 8: Flow rate and flow velocity of AVG 3 brachial artery inflow. 
 
 
Figure 9: Flow rate and flow velocity of AVG 2 proximal artery-graft anastomosis. 
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Figure 10: Flow rate and velocity of the distal graft-vein anastomosis of AVG 2. 
 
Due to the limited results available from scanning the AVG patients, only one set of 
data was available for the analysis. The artery-graft anastomosis had a flow volume 
of 660 ml/min. and a velocity of 62 cm/sec. The flow increased proximally to 1 681 
ml/min. and the velocity to 85 cm/sec. The  graphs (Figures 8-11) demonstrate how 
different the flow versus time patterns are in each area of interest.  
 
 
Figure 11: Comparison of flow rates and velocities through artery-graft and graft-
vein anastomoses of AVG 2. 
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Duplex Dopplers 
Peak systolic velocity (PSV) over the areas of interest scanned were recorded. PSV 
was fastest at the artery-graft anastomosis (307 cm/sec), and slowed through the 
graft to 217 cm mid-graft. All velocities recorded in AVF 5 were remarkably similar 
at 99.0 cm/sec to 107 cm/sec, but there was concern about the accuracy of these 
results.  
 
Flow velocity 
 AVF 5 AVG 2 
 MRI Duplex 
Doppler 
MRI Duplex 
Doppler 
Brachial 
artery 
93.2 107.8 60.1 – 
Arterial 
anastomosis 
22.9 99.9 63.1 307.0 
Mid-
fistula/graft 
24.7 99.9 – 217.0 
Graft-vein 
anastomosis 
– – 85.0 – 
Table 4: Comparison of flow velocity measured by MRI calculation and duplex 
Doppler. 
 
3.4 Discussion 
The aim of this study was to develop a novel imaging technique using 4D MRI 
technology to image dialysis access. The aim was not only to image the fistulae, but 
also to see whether the haemodynamic data could be used for computational 
modelling, which has previously been shown to generate accurate haemodynamic 
models of dialysis access15. Once the models have been built, they will be used to 
test various hypotheses to improve the access.  
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The scans on volunteers closely reflected the cardiac cycle. The later scans of 
dialysis patients, both the fistulae and the grafts, generated adequate 3D flow data, 
which allowed the generation of quantitative data of flow volumes and velocities. 
These studies demonstrated the complex nature and turbulence of the flows through 
a fistula. The access scans showed increased velocities and flow volumes through the 
brachial arteries as well as the access itself, in comparison to healthy volunteers. The 
marked increase in flow rate and velocity through the brachial arteries of the dialysis 
access in comparison to the healthy volunteers is thought to be due to loss of 
capillary network resistance in the arteriovenous access limb.  
 
The initial access scans were limited, as flow velocities were initially vastly 
underestimated when determining MRI scan settings. However, as the study 
progressed, these settings were improved. This culminated in the complete scan of 
AVF 7, which not only generated 2D data, but also 4D data, and allowed full use of 
the 4D software, producing streamlining particle tracking images. Therefore, 
subsequent studies on haemodialysis access using this technique would be able to 
make use of the optimised 4D MRI scan protocol.  
 
Comparison of results with currently validated imaging and velocity calculations 
should be interrogated further. Although 4D MRI has been validated previously on 
larger vessels, the added complexity of flows in arteriovenous fistulae and the fact 
that this was an entirely novel protocol means that further research is required. 
Although we attempted validation in this pilot study, it was not the primary aim of 
the study, and we were hampered by logistical constraints. The early lessons learnt 
included information about the expected velocities of flows in the vessels as well as 
MRI coil placement. This proved to be challenging throughout the pilot.  
 
Coil placement was a particular challenge when scanning arteriovenous grafts, as the 
upper-arm coil was a standard size and did not always cover both the proximal and 
distal anastomoses. This also meant that central veins did not form part of the 
imaging. This is of clinical relevance, as a proximal stenosis is a major cause of both 
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failure to mature as well as access thrombosis16. Should this imaging technology be 
considered for clinical use, this problem would have to be addressed.  
   
This was an entirely novel application of 4D MRI. Development of the scan protocol 
required a collaborative team effort between surgeons, imaging specialists and 
biomedical engineers. Presenting the data in a universally understood way was 
challenging. This resulted in some limitations early in the pilot, and emphasised the 
importance of careful and thoroughly understood communication in innovative 
interdisciplinary projects. Further areas of research following this pilot project 
should include longitudinal studies of access to assess how haemodynamics change, 
as the access matures over time. This would also provide valuable information for 
model building to allow for possible clinical changes.  
 
3.4 Conclusion 
4D flow-sensitive MRI can produce adequate quantitative data for computational 
model building. Further research is required to validate it in this specific clinical 
area, as well as refine imaging and processing.  
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CHAPTER 4  
APPENDICES 
  
4.1 Consent form 
UNIVERSITY OF  
CAPE TOWN  
  
    
 
 
Department of Surgery  
Division of General Surgery  
Prof D Kahn, MB ChM (UCT), FCS(SA)  
Head of Department: Surgery – Division and Organ Transplantation  
J45 Room 23, Old Main Building, Groote Schuur Hospital  
Observatory, 7925, South Africa  
Tel.: +27 (0)21 406 6229  
Fax: +27 (0)21 448 6461  
Email: Delawir.Kahn@uct.ac.za   
Consent for taking part in a research study:  
Imaging of haemodialysis fistulas and grafts  
 
Why is this study being done?  
This is a study that hopes to gather information about the fistula or graft in your arm 
that to which the needles of the haemodialysis machine are connected during your 
haemodialysis sessions. We hope that this will give a better understanding of why 
these grafts and fistulae cause problems and why they sometimes fail. We can then 
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use this information to try to improve fistulae or grafts, for example how long they 
last, and minimise the problems they cause.   
  
Why are you being asked to participate?  
You are being asked to participate because you have a fistula or graft in your arm 
that is used for your haemodialysis session, or we want you to take part as a healthy 
person for comparison.   
  
How long will you participate in this research? How much of your time will be 
needed? Do you need to take time off work?  
You will participate in this study for about two hours. You will not need to take time 
off work, as the scans will be done either on a weekday at 6 p.m. or over a weekend.  
  
What will happen if you decide to take part in the study?  
We will take images of your upper arm in the location of the graft or fistula, or your 
upper arm in a similar region if you belong to the group of healthy participants. The 
images will be taken using a magnetic resonance imaging machine. We may also 
take a Doppler ultrasound scan of your arm to look at your fistula or graft.  
  
What are the risks and discomforts of this study?  
The magnetic resonance imaging procedure is not painful or dangerous, and there are 
no known harmful long-term effects. The ultrasound Doppler procedures are not 
painful or dangerous and do not involve any risks. You will not require any drips, 
injections or medication for the scans. You may feel nervous being in the scanning 
machine because it is a tube-like space around you.   
  
Are there any benefits to you for being in the study?  
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No, there are no benefits to you.   
What other choices do you have?  
Your participation is voluntary. You have the choice of not taking part in this study. 
Such a decision will not affect in any way your current or future medical treatment, 
e.g. your haemodialysis sessions.  
  
What if something goes wrong? 
The University of Cape Town (UCT) undertakes that, in the event of you suffering 
any significant deterioration in health or well-being, or from any unexpected 
sensitivity or toxicity that is caused by your participation in this study, it will provide 
immediate medical care. UCT has appropriate insurance cover to provide prompt 
payment of compensation for any trial-related injury according to the guidelines 
outlined by the Association of the British Pharmaceutical Industry, ABPI 1991. 
Broadly speaking, the ABPI guidelines recommend that the insured company (UCT), 
without legal commitment, should compensate you without you having to prove that 
UCT is at fault. An injury is considered trial-related if, and to the extent that, it is 
caused by study activities. You must notify the study doctor immediately of any side 
effects and/or injuries during the trial, whether they are research-related or other 
related complications. 
 
UCT reserves the right not to provide compensation if, and to the extent that, your 
injury came about because you chose not to follow the instructions that you were 
given while you were taking part in the study. Your right in law to claim 
compensation for injury where you prove negligence will not be affected. Copies of 
these guidelines are available on request. 
 
What will happen when the study is over?  
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Nothing will be required from you when the study is over. We will present findings 
of the study at conferences and in publications, for example in medical journals and 
in reports that students have to write.  
  
Who can you contact or speak to if you have any questions about the study?  
You can contact Associate Professor Thomas Franz (tel.: 021 406 6418; email 
thomas.franz@uct.ac.za), who is the principal investigator, and Dr. Jennifer Downs 
(tel.: 083 324 2106; email jen.s.downs@gmail.com), who will be involved in 
selecting the participants for this study.  
  
If you have any questions regarding your rights or welfare as participant in this 
study, you can contact the Human Research Ethics Committee of the Faculty of 
Health Sciences at the University of Cape Town, using the contact details below. 
Please mention the reference number HREC/REF454/2013.  
  
Faculty of Health Sciences Human Research Ethics Committee  
Room E52-24, Groote Schuur Hospital, Old Main Building  
Observatory, 7925  
Tel.: +27 (0)21 406 6492 
Fax: +27 (0)21 406 6411  
Email: sumayah.ariefdien@uct.ac.za   
  
Consent  
 I, the undersigned, hereby consent to taking part in the study described above. 
The details of the scans and study have been fully explained to me.   
 I understand that participation in this study is voluntary and I am under no 
obligation to participate.   
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 I understand that no experimental device will be implanted into my body and that 
no tissue will be removed from my body, and no medications or contrast will be 
injected into my body.   
 I understand that participating in this study will in no way influence my 
treatment nor will it have any detrimental effect on my health.   
 I understand that refusing to participate in the study will not prejudice me in any 
way.  
  
 Patient name:    
 
Patient signature:    
 
Date:    
 
Place:    
 
Investigator name:    
 
    Investigator signature:    
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4.2 Patient information sheet 
UNIVERSITY OF CAPE TOWN 
 
Department of Surgery  
Division of General Surgery  
Prof D Kahn, MB ChM (UCT), FCS(SA)  
Head of Department: Surgery – Division and Organ Transplantation  
J45 Room 23, Old Main Building, Groote Schuur Hospital  
Observatory, 7925, South Africa  
Tel.: +27 (0)21 406 6229  
Fax: +27 (0)21 448 6461  
Email: Delawir.Kahn@uct.ac.za   
 
Participant information:  
Study on imaging of haemodialysis fistulae and grafts 
 
Dear participant 
 
Thank you for being willing to be a participant in our research. This letter will 
provide you with information on the study and your involvement. 
 
Why is this study being done? 
This is a study that hopes to gather information about the fistula or graft in your arm 
that to which the needles of the haemodialysis machine are connected during your 
haemodialysis sessions. 
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We will do a magnetic resonance imaging scan of your arm in the region of the 
fistula or graft, which will tell us both how this fistula or graft looks and how the 
blood flows inside it. 
 
Hopefully this will allow us to better understand why these grafts and fistulae cause 
problems and why they sometimes fail. We can then use this information to try to 
improve fistulae or grafts, for example how long they last, and minimise the 
problems they cause. 
 
Who are the researchers that are involved is this study? 
The study is performed by a team of clinicians and researchers of the University of 
Cape Town and Groote Schuur Hospital – from the Department of Surgery, the 
Renal Unit, the Cardiovascular Research Unit, the Medical Imaging Research Unit 
and the Centre for Research in Computational and Applied Mechanics.  
 
In addition, we work with two external researchers, one from the Northwestern 
University in Chicago, and one from Siemens Medical Solutions, the company who 
makes the magnetic resonance imaging (MRI) machine we will use in this study. 
 
Data obtained from you in this study will also be used by three Masters students and 
one Doctoral student at the University of Cape Town in their research projects. 
 
Why are you being asked to participate? 
You are being asked to participate because you have a fistula or graft in your arm 
that is used for your haemodialysis session, or we want you to take part as a healthy 
person for comparison. 
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The study has participants in three groups: 1) participants with a fistula in one upper 
arm, 2) participants with a graft in one upper arm, and 3) participants that do not 
have a fistula or graft. In the participants without a graft or fistula, we will measure 
how the blood flows in the healthy upper arm, to find differences that a fistula or 
graft causes to the blood flow. 
 
How many people will take part in the study? 
Nine people will take part in this study: three with a graft, three with a fistula and 
three without a graft or fistula. 
 
How long will the study last? 
The entire study will last for six to 12 months, but you only need to take part once 
for about two hours. 
 
What do we do to decide if you are eligible to take part? 
We will get information from your hospital record, including when you received 
your haemodialysis graft or fistula and whether you are a candidate for a kidney 
transplant. If you’re a participant without a haemodialysis graft or fistula, we will 
confirm that you do not have a history of vascular diseases and had no surgery on the 
upper arm. 
 
We will check that you do not suffer of fear being in small spaces and that you do 
not have any medical or metal implants, such as a pacemaker for your heart. 
 
We will also discuss with you what will happen if you participate and if you would 
feel comfortable with everything. 
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What will happen if you decide to take part in the study? 
We will take images of your upper arm in the location of the graft or fistula, or your 
upper arm in a similar region if you belong to the group of healthy participants. The 
images will be taken using a magnetic resonance imaging machine. This is a tube-
like machine containing a magnet in which you lie. The machine takes extremely 
detailed pictures of your arm and the blood vessels inside it, similar to X-ray images. 
 
The scanning will take place in the Department of Radiology at the Groote Schuur 
Hospital, Ward C7. We will need 30 minutes to familiarise you with the scanner and 
to get you ready before your scan takes place. After that, the scanning itself will take 
approximately 45 minutes. We will take the images either on a weekday at 6 p.m. or 
on a Saturday or Sunday during the day. 
 
At the beginning, we will ask you to change into a gown and remove metal objects, 
such as watches, credit cards, hairpins and writing pens before going into the 
scanner. The reason is that such metal objects may be damaged or pulled away from 
your body by the magnet. 
 
You will then lie on a soft plastic bed that slides into the magnetic resonance 
imaging scanner (the tube-like machine). We will ask you to lie as still as possible 
while the pictures are being taken. When the scanner takes the pictures, the bed may 
shake slightly and you may hear loud banging noises from time to time. 
 
We may also take a Doppler ultrasound scan of your arm to look at your fistula or 
graft; you may have already had one in the Renal Unit. This is a quick, painless 
procedure done by holding an ultrasound probe on your arm over your fistula or 
graft, and will also record the blood flow in the fistula or graft. 
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It takes approximately 15 minutes and will be done before or after the magnetic 
resonance imaging scan at the same location in the hospital. We would like to do this 
ultrasound scan so that we can compare the ultrasound scan with the magnetic 
resonance imaging scan. 
 
What are the risks and discomforts of this study? 
Any medical devices or pieces of metal implanted in your body or under your skin 
can be damaged by the scanning machine (but can also damage the scanning 
machine itself). 
 
Please let us know if you, for example, have a pacemaker for your heart or a metal 
part that is used to fix a broken bone in the arm or leg, as you cannot participate in 
this study in such cases. 
 
The magnetic resonance imaging scan requires that you lie in a narrow tube. Please 
also let us know if you have a fear of being in a small space. 
 
You may feel nervous being in the scanning machine because it is a tube-like space 
around you. 
 
We will give you earplugs to protect your ears and headphones so we can talk to 
you. You may also get a blanket so that you don’t get cold during the scanning 
procedure. We will not start with taking images until you tell us that you are 
comfortable. 
 
You will be able to stop the scan at any time by squeezing a ball that you will hold in 
one hand, and you can talk to us at any time during the scanning procedure using an 
intercom that is built into the scanner. 
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The magnetic resonance imaging procedure is not painful or dangerous, and there are 
no know harmful long-term effects. The ultrasound Doppler procedures are not 
painful or dangerous and do not have any a risk for you. You will not require any 
drips, injections or medication for the scans. 
 
Are there any benefits to you for being in the study? 
No, there are no benefits to you. There may be benefits for patients like you in the 
future if the study leads to improvements of haemodialysis grafts or fistulae. 
 
What other choices do you have? 
Your participation is voluntary. You have the choice of not taking part in this study. 
Such a decision will not affect in any way your current or future medical treatment, 
e.g. your haemodialysis sessions. 
 
What if something goes wrong? 
The University of Cape Town (UCT) undertakes that, in the event of you suffering 
any significant deterioration in health or well-being, or from any unexpected 
sensitivity or toxicity that is caused by your participation in the study, it will provide 
immediate medical care. UCT has appropriate insurance cover to provide prompt 
payment of compensation for any trial-related injury according to the guidelines 
outlined by the Association of the British Pharmaceutical Industry, ABPI 1991.  
 
Broadly speaking, the ABPI guidelines recommend that the insured company (UCT), 
without legal commitment, should compensate you without you having to prove that 
UCT is at fault. An injury is considered trial-related if, and to the extent that, it is 
caused by study activities. You must notify the study doctor immediately of any side 
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effects and/or injuries during the trial, whether they are research-related or other 
related complications. 
 
UCT reserves the right not to provide compensation if, and to the extent that, your 
injury came about because you chose not to follow the instructions that you were 
given while you were taking part in the study. Your right in law to claim 
compensation for injury where you prove negligence will not be affected. Copies of 
these guidelines are available on request. 
 
What will happen when the study is over? 
Nothing will be required from you when the study is over. We will present findings 
of the study at conferences and in publications, for example in medical journals and 
in reports that students have to write. 
 
Will your test results be shared with you? 
No, the results of the imaging tests will not be shared with you. 
 
Will the results of the research be shared with you? 
No, the results of the research will not be shared with you. 
 
Will any of your blood, tissue or other samples be stored and used for research 
in the future? 
No, we will not take or store any blood, tissue or other samples from you. 
 
Will you receive any reward (money or food vouchers) for taking part in this 
study? 
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Yes. We will refund your costs for transport to Groote Schuur Hospital for the 
imaging procedures and back home up to R200. We will also give a voucher of R50 
for refreshments at Groote Schuur Hospital. 
 
Who will see the information that is collected about you during the study? 
The researchers and students involved in this study will see the data obtained from 
you, but without your personal information. Only the principal investigator (A/Prof 
Thomas Franz) and the clinical registrar who is involved in your recruitment (Dr. 
Jennifer Downs) will see your personal information. 
We will also send report and data obtained in this study without your personal 
information to Siemens Medical Solutions GmbH, the manufacturer of the magnetic 
resonance imaging machine we use in this study. This is part of a collaboration 
agreement that allows us to use an analysis software developed by Siemens. 
 
Will your data be confidential? 
Your personal information will be confidential and we will use pseudonyms instead 
of your name to recognise your data. Any personal information will be kept in a 
secure location. 
 
Who can you contact or speak to if you have any questions about the study? 
You can contact Associate Professor Thomas Franz (tel.: 021 406 6418; email 
thomas.franz@uct.ac.za), who is the principal investigator, and Dr. Jennifer Downs 
(tel.: 083 324 2106; email jen.s.downs@gmail.com), who will be involved in 
selecting the participants for this study. 
 
If you have any questions regarding your rights or welfare as participant in this 
study, you can contact the Human Research Ethics Committee of the Faculty of 
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Health Sciences at the University of Cape Town, using the contact details below. 
Please mention the reference number HREC/REF454/2013. 
 
Faculty of Health Sciences Human Research Ethics Committee 
Room E52-24, Groote Schuur Hospital, Old Main Building 
Observatory, 7925 
Tel.: +27 (0)21 406 6492  
Fax: +27 (0)21 406 6411 
Email: sumayah.ariefdien@uct.ac.za 
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